Induction of regional chemokine expression in response to human umbilical cord blood cell infusion in the neonatal mouse ischemia-reperfusion brain injury model.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
03
2019
accepted:
30
07
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
12
3
2020
Statut:
epublish
Résumé
Regenerative medicine using umbilical cord blood (UCB) cells shows promise for the treatment of cerebral palsy. Although the efficacy of this therapy has been seen in the clinic, the mechanisms by which UCB cells interact and aid in the improvement of symptoms are not clear. We explored the chemokine expression profile in damaged brain tissue in the neonatal mouse ischemia-reperfusion (IR) brain injury model that was infused with human UCB (hUCB) cells. IR brain injury was induced in 9-day-old NOD/SCID mice. hUCB cells were administered 3 weeks post brain injury. Chemokine expression profiles in the brain extract were determined at various time points. Inflammatory chemokines such as CCL1, CCL17, and CXCL12 were transiently upregulated by 24 hours post brain injury. Upregulation of other chemokines, including CCL5, CCL9, and CXCL1 were prolonged up to 3 weeks post brain injury, but most chemokines dissipated over time. There were marked increases in levels of CCL2, CCL12, CCL20, and CX3CL1 in response to hUCB cell treatment, which might be related to the new recruitment and differentiation of neural stem cells, leading to the induction of tissue regeneration. We propose that the chemokine expression profile in the brain shifted from responding to tissue damage to inducing tissue regeneration. hUCB cell administration further enhanced the production of chemokines, and chemokine networks may play an active role in tissue regeneration in neonatal hypoxic-ischemic brain injury.
Identifiants
pubmed: 31483787
doi: 10.1371/journal.pone.0221111
pii: PONE-D-19-07879
pmc: PMC6726228
doi:
Substances chimiques
Biomarkers
0
Chemokines
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221111Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Cell Biol. 2002 Feb 4;156(3):555-65
pubmed: 11827984
Stem Cells. 2004;22(1):109-18
pubmed: 14688397
Shock. 2005 Jul;24(1):74-84
pubmed: 15988324
Mol Cell Neurosci. 2006 Feb;31(2):315-25
pubmed: 16300961
Stem Cells Dev. 2005 Oct;14(5):576-86
pubmed: 16305342
Annu Rev Immunol. 2007;25:787-820
pubmed: 17291188
J Invest Dermatol. 2007 Mar;127(3):514-25
pubmed: 17299434
J Immunol. 2008 Jun 1;180(11):7590-6
pubmed: 18490761
J Cereb Blood Flow Metab. 2011 Apr;31(4):1036-50
pubmed: 21045863
J Neuroinflammation. 2012 Feb 16;9:33
pubmed: 22340958
Stem Cells. 2013 Mar;31(3):581-91
pubmed: 23281216
Brain Res. 2013 Jun 23;1517:122-32
pubmed: 23602964
Blood. 2013 Jul 25;122(4):491-8
pubmed: 23673863
J Neuroimmunol. 2013 Oct 15;263(1-2):75-82
pubmed: 23968561
PLoS One. 2013 Dec 31;8(12):e83833
pubmed: 24391835
Cytokine. 2016 Jan;77:227-37
pubmed: 26463515
Wien Klin Wochenschr. 2016 Jan;128(1-2):20-7
pubmed: 26542133
Adv Wound Care (New Rochelle). 2015 Nov 1;4(11):623-630
pubmed: 26543676
Pract Neurol. 2016 Jun;16(3):184-94
pubmed: 26837375
Nat Rev Immunol. 2017 Jan;17(1):49-59
pubmed: 27916979
Neuropharmacology. 2017 Mar 1;114:146-155
pubmed: 27923568
Stem Cell Res Ther. 2017 Feb 7;8(1):26
pubmed: 28173860
Expert Opin Biol Ther. 2017 Jun;17(6):691-699
pubmed: 28379044
Cell Mol Life Sci. 2017 Sep;74(18):3275-3291
pubmed: 28389721
J Neuroinflammation. 2017 Apr 24;14(1):89
pubmed: 28438224
Life Sci. 2017 Sep 1;184:87-94
pubmed: 28624392
Neurochem Int. 2018 Jan;112:146-158
pubmed: 28629771
Stem Cells Transl Med. 2017 Dec;6(12):2071-2078
pubmed: 29080265
Aging Dis. 2018 Apr 1;9(2):287-295
pubmed: 29896417
Front Cell Neurosci. 2018 Sep 27;12:323
pubmed: 30319362